Core Insights - Co-Diagnostics reported a significant decline in revenue for the full year 2025, with total revenue of $0.6 million compared to $3.9 million in 2024, primarily due to lower grant revenue [2] - The company experienced an operating loss of $50.2 million in 2025, up from a loss of $40.1 million in 2024, largely driven by an $18.9 million non-cash impairment charge related to intangible assets [2][3] - The net loss for 2025 was $46.9 million, or $35.25 per share, compared to a net loss of $37.6 million, or $37.22 per share in 2024, reflecting the impact of impairment charges and reduced grant revenue [2][3] Financial Performance - Revenue for 2025 was $0.6 million, a decrease of 84% from $3.9 million in 2024 [2] - Operating expenses rose to $50.6 million in 2025 from $43.0 million in 2024, influenced by the impairment charge [2] - Adjusted EBITDA loss improved to $28.0 million in 2025 from a loss of $33.5 million in 2024 [2] Cash Position - As of December 31, 2025, cash, cash equivalents, and marketable investment securities totaled $11.9 million, down from $29.7 million at the end of 2024 [2] - The company closed two offerings, raising $3.8 million and $7.0 million through the sale of common stock [2] Strategic Developments - Co-Diagnostics is advancing its joint ventures, including CoSara Diagnostics in India and CoMira Diagnostics in Saudi Arabia, focusing on regulatory progress and manufacturing readiness [2][3] - The company is progressing with clinical evaluations for an upper respiratory multiplex test and expanding its AI capabilities within its diagnostic platform [2][3] - A new international patent was granted in Australia, enhancing the company's intellectual property portfolio [2] Future Outlook - The CEO emphasized the company's focus on executing its strategy centered on expanding its global footprint and advancing clinical programs toward regulatory milestones [3] - Plans for an initial FDA 510(k) submission for an upper respiratory test are underway, with the potential to incorporate COVID testing later if necessary [3]

Core Insights - Insight Molecular Diagnostics Inc. has submitted GraftAssureDx, a kitted dd-cfDNA assay, to the FDA for regulatory review, marking a significant milestone after 12 years of clinical development and 3 years of technical product development [1] - The company has seen a doubling in interest from transplant centers, now engaging with 37 centers in the U.S. and 11 internationally, which represents over 25% of annual transplants in the U.S. [3][4] - The addressable market for regulated transplant rejection testing is estimated at around $2 billion, with the company positioned to lead in this emerging market [4][5] FDA Submission and Market Readiness - The FDA has a 150-day review process for de novo submissions, and the company anticipates receiving authorization within this timeframe [5] - The company has prepared a review-ready submission with sufficient analytical data and clinical evidence to support the assay's safety and effectiveness [8] - The company expects to receive U.K. CE marking via self-certification in Q2 2026 [6] Financial Overview - For the full year 2025, the company reported revenue of $4.1 million, up from $1.9 million in 2024, with Q4 2025 revenues at $1.1 million [30] - The gross profit for 2025 was $2.3 million, reflecting a gross margin of 56.7%, compared to a gross profit of $740,000 in the previous year [32] - Operating expenses for 2025 totaled $53.4 million, including significant non-cash impairment losses [32] Research and Development - Research and development expenses increased by 62% year-over-year to $15.9 million, reflecting investments in kitted product development [32] - The company is also focusing on expanding GraftAssure's utility into heart transplantation, supported by a recent $26 million financing [6][12] Clinical Utility and Market Trends - The company believes that the organ transplant rejection testing market is shifting towards active management of patients post-transplant, enabling earlier detection of organ rejection [17] - The GraftAssure assay is designed to measure both absolute and relative quantities of dd-cfDNA, potentially improving the detection of T-cell mediated rejection [21][22] - The company anticipates that the demand for decentralized molecular testing will continue to grow, supported by emerging clinical data and publications [5][16] Strategic Goals for 2026 - The company aims to transition into a commercialization-stage company in 2026, with goals including obtaining regulatory approval for GraftAssureDx and commencing sales of the research-use-only version of its kits [12][13] - The company plans to engage 50 U.S. transplant centers for its GALACTIC registry study, which will help build a scientific case for the combined score of dd-cfDNA measurements [13]

Investor Presentation NASDAQ:IMDX March 2026 iMDxinc.com Forward-Looking Statements This presentation contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that predict or indicate future events or trends or t ...

Core Insights - The company achieved a record Q4 test volume of 3,664, surpassing the target range of 2,500 to 3,000, attributed to enhanced sales team productivity and a solidified market presence [1] - A contract was secured with the U.S. Department of Veterans Affairs (VA) under the Federal Supply Schedule, validating the Medicare pricing of $938 and providing access to 9 million enrolled veterans [1] - The company identified a 'de facto' coverage pathway with UnitedHealthcare by utilizing endoscopy guidelines that recognize EsoGuard as an appropriate indicator for EGD procedures [1] Commercial Strategy - The commercial team has shifted its focus from high-volume event-based testing to higher-value Medicare and VA clinical populations in anticipation of upcoming reimbursement changes [1] - Real-world data from 12,000 patients was released, confirming a 95% technical success rate and safety profile, which management is leveraging to distinguish EsoGuard from outdated sponge-based competitors [1] Regulatory Context - The delay in the Medicare draft Local Coverage Determination (LCD) is attributed to administrative and logistical backlogs at MolDx, rather than concerns regarding clinical utility [1]

Commercial Highlights - EsoGuard test volume in Q4 reached 3,664, exceeding the target range of 2,500 to 3,000 tests per quarter, representing a 29% increase from 2025 [1] - Revenue for Q4 was $1,500,000, reflecting a 24% increase from 2025 [1] - The company has secured a U.S. Department of Veterans Affairs (VA) contract for EsoGuard, aligning pricing with the established Medicare rate of $938 [6][7] - The VA serves approximately 9,000,000 enrolled veterans annually, with a significant portion expected to be recommended for testing due to higher risks of GERD and esophageal disease [6][7] Clinical Evidence and Testing Performance - Positive data from a study involving nearly 12,000 patients confirmed the technical success rate for EsoCheck cell collection at 95%, with 95% of procedures completed in under two minutes [8][10] - EsoGuard and EsoCheck demonstrated scalability and viability in real-world settings, setting a high standard for clinically viable precancer screening tools [10][11] Reimbursement and Coverage Updates - The company is awaiting the publication of a draft Local Coverage Determination (LCD) for Medicare, with confidence in a positive outcome based on previous Contractor Advisory Committee meetings [12][13] - Engagements with commercial payers, including UnitedHealthcare, have progressed positively, with EsoGuard included as an appropriate indication for endoscopy [15][52] - The company is actively pursuing in-network coverage through various pathways, including credentialing with UnitedHealthcare and discussions with other payers like Cigna and Anthem [16][17] Financial Performance - Cash at year-end December 31 was $34,700,000, with an average burn rate of $11,100,000 per quarter [34][35] - The company sold over 3,600 tests in Q4, with a billable value exceeding $9,000,000, resulting in recognized revenue of $1,500,000 [40][46] - Non-GAAP loss for the year was $44,000,000, with a non-GAAP net loss per share of $0.10 in Q4, showing improvement compared to the previous year [45] Future Outlook - The company anticipates significant growth in testing volume as it engages with the VA and secures Medicare coverage, aiming to convert demand into revenue [29][30] - The total addressable market within the VA is estimated to be a couple of million patients, based on existing guidelines recommending testing for a subset of the veteran population [83]

Financial Data and Key Metrics Changes - The company reported a test volume of 3,664 for the fourth quarter, exceeding the target range of 2,500-3,000 tests per quarter, representing a 29% increase from the third quarter of 2025 [4] - Revenue for the fourth quarter was $1.5 million, reflecting a 24% increase from the third quarter of 2025 [4][36] - Cash at year-end was $34.7 million, with an average burn rate of $11.1 million per quarter [32] Business Line Data and Key Metrics Changes - The EsoGuard test volume increased significantly, with over 3,600 tests sold in the fourth quarter, leading to recognized revenue of $1.5 million [36][41] - The company is focusing on transitioning to target both Medicare and the VA, with a notable contract awarded by the U.S. Department of Veterans Affairs for EsoGuard [5][6] Market Data and Key Metrics Changes - The company is engaging with the VA, which serves approximately 9 million enrolled veterans annually, many of whom are at higher risk for esophageal diseases [6][19] - The percentage of test volume from Medicare beneficiaries increased to around 16% in the fourth quarter, up from 10%-12% in prior quarters [67] Company Strategy and Development Direction - The company aims to convert its established demand generation into revenue, focusing on the VA and Medicare as key markets moving forward [26] - The strategy includes reallocating resources to enhance engagement with Medicare and the VA while maintaining test volume [21][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming Medicare coverage, indicating that logistical delays are the primary reason for the wait [10][11] - The company believes it is at an inflection point, with extensive groundwork laid for future success, particularly in EHR integration [27][28] Other Important Information - The company has secured positive data from a large real-world study on EsoGuard, which is expected to bolster its case for reimbursement and payer engagement [7][9] - The company is actively pursuing in-network coverage with major payers, including UnitedHealthcare, and has initiated the credentialing process [12][51] Q&A Session Summary Question: Increase in test volume - Management indicated that the recent increase in test volume is not directly attributable to the VA but reflects improved team productivity and ongoing efforts towards Medicare [46][47] Question: Health plan coverage discussions - The company views the inclusion of EsoGuard in UnitedHealthcare's endoscopy guidelines as a form of de facto coverage and is moving towards credentialing and contracting discussions [48][50] Question: Medicare mix and claims - The Medicare component of test volume has grown sequentially, with expectations for further increases as the company continues to focus on this demographic [67][68] Question: Sales and marketing expenses - The increase in sales and marketing expenses in the fourth quarter is expected to stabilize around $5 million per quarter moving forward, with some annual compensation expenses included [77][78]

Nasdaq: LUCD Q4 2025 Business Update March 26, 2026 Lishan Aklog MD Dennis McGrath Chairman & CEO CFO Disclaimer 2 4 – 4Q25 EsoGuard test volume: 3,664 – 4Q25 Revenue: $1.5M – Awarded U.S. Department of Veterans Affairs (VA) contract for EsoGuard, expanding access across the nation's largest integrated healthcare system – Announced positive data from the largest reported real-world experience of esophageal precancer detection, evaluating EsoGuard and EsoCheck in nearly 12,000 at-risk patients Business Updat ...

Core Insights - HeartFlow utilizes advanced AI and computational fluid dynamics for non-invasive cardiac diagnostics, enhancing diagnostic accuracy and patient management in cardiovascular care [1] - The company reported a 40% year-over-year revenue increase for 2025, reaching approximately $176 million, with Q4 revenue at $49.1 million and gross margins nearing 80% [7] - Management projects revenue for 2026 to be between $218 million and $222 million, indicating continued double-digit growth [7] Company Operations - HeartFlow generates revenue through the sale of its diagnostic platform and related healthcare information services to hospitals and cardiology practices [2] - The company is positioned as a leader in the medical healthcare information services sector, focusing on innovation and clinical impact [1] Insider Activity - Rogers Campbell, the chief medical officer, exercised 67,017 options and sold 64,533 shares for approximately $1.66 million, reflecting a 72.8% reduction in direct common stock holdings [5][3] - The transaction was executed under a Rule 10b5-1 plan, indicating routine liquidity rather than a strategic shift [4][6] Market Performance - Despite ongoing net losses, HeartFlow's stock has remained relatively stable over the past year, attributed to strong top-line growth and continued investment in commercialization and R&D [7][8] - The insider activity is viewed as mechanical, with the focus on the company's ability to sustain high growth and move towards profitability [8]

Company Overview - GRAIL is a biotechnology company focused on blood-based multi-cancer early detection and diagnostic solutions, utilizing advanced genomics and data science to transform cancer screening and diagnosis at scale [5] - The company has a market capitalization of $1.9 billion and reported a revenue of $147.2 million for the trailing twelve months (TTM), with a net income loss of $408.35 million [4] Recent Transaction - On February 17, 2026, One Fin Capital Management completely exited its position in GRAIL, selling approximately 380,000 shares valued at $22.47 million [1][2] - Following this liquidation, GRAIL now represents 0% of One Fin's 13F assets under management (AUM), a decrease from 7.4% in the previous period [7] Performance Metrics - As of the last trading day, GRAIL's shares were priced at $46.84, reflecting a 68% increase over the past year, significantly outperforming the S&P 500, which rose about 15% during the same timeframe [7] Business Insights - GRAIL's revenue primarily comes from sales of proprietary diagnostic tests and related services, targeting healthcare providers, clinicians, and asymptomatic individuals over 50 seeking proactive cancer screening solutions [8] - The company has sold over 185,000 Galleri tests, contributing to its revenue growth [9] Market Sentiment - The recent sale by One Fin indicates a cautious approach in light of GRAIL's heavy losses and execution risks associated with regulatory approval and market adoption [9] - A significant drop of approximately 50% in GRAIL's stock price following earnings highlights the volatility and fragility of market sentiment when expectations exceed fundamental performance [10]

Core Viewpoint - Abbott is set to finalize the acquisition of Exact Sciences on March 23, 2026, following the receipt of all necessary regulatory approvals, positioning the company to lead in the rapidly growing cancer screening and diagnostics market, thereby expanding its service to millions more individuals [1]. Group 1 - The acquisition of Exact Sciences will enable Abbott to enter and lead in the cancer screening and diagnostics segments [1]. - The transaction is expected to serve millions of additional people, indicating a significant market expansion for Abbott [1].